Dataset Information
Cyclin-dependent kinase 5 acts as a promising biomarker in clear cell Renal Cell Carcinoma.
Ontology highlight
ABSTRACT: Background
This research provides the first evidence of CDK5 in ccRCC prognosis and correlation with different p21 expression in overall survival (OS) analysis.Methods
The data from both of The Cancer Genome Atlas (TCGA) and Gene Expression of Normal and Tumor Tissue (GENT) were analyzed for determining the expression of CDK5 in kidney cancer. Tissue microarray that made by using 150 ccRCC samples was used in immunohistochemistry (IHC) analysis. A validation of OS cohort was extracted from Oncomine database.Results
The CDK5 expression was significantly lower in cancer tissue compared with normal in TCGA (p ConclusionsTogether, our findings provided the first evidence that CDK5 was acting as a promising biomarker in ccRCC patients, and co-expression of CDK5 and p21 is an independent prognostic for overall survival. IHC analysis of CDK5 and p21 on cancer tissues after surgery may help to evaluate and predict the outcome of ccRCC patients.
SUBMITTER: Zhu L
PROVIDER: S-EPMC6636025 | biostudies-literature | 2019 Jul
REPOSITORIES: biostudies-literature
Publications
Cyclin-dependent kinase 5 acts as a promising biomarker in clear cell Renal Cell Carcinoma.
BMC cancer 20190716 1
<h4>Background</h4>This research provides the first evidence of CDK5 in ccRCC prognosis and correlation with different p21 expression in overall survival (OS) analysis.<h4>Methods</h4>The data from both of The Cancer Genome Atlas (TCGA) and Gene Expression of Normal and Tumor Tissue (GENT) were analyzed for determining the expression of CDK5 in kidney cancer. Tissue microarray that made by using 150 ccRCC samples was used in immunohistochemistry (IHC) analysis. A validation of OS cohort was extr ...[more]